{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptSortName=Health+and+Social+Care&min-ddpModified.=2019-09-09T18%3A00%3A06.953Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answeringDeptSortName=Health+and+Social+Care&min-ddpModified.=2019-09-09T18%3A00%3A06.953Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptSortName=Health+and+Social+Care&_metadata=all&min-ddpModified.=2019-09-09T18%3A00%3A06.953Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&answeringDeptSortName=Health+and+Social+Care&min-ddpModified.=2019-09-09T18%3A00%3A06.953Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptSortName=Health+and+Social+Care&min-ddpModified.=2019-09-09T18%3A00%3A06.953Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptSortName=Health+and+Social+Care&min-ddpModified.=2019-09-09T18%3A00%3A06.953Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1737793", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1737793/answer", "answerText" : {"_value" : "

No assessment of the merits of running a public awareness campaign to remove all COVID-19 signs has been made.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"} } , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"} , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"} , "dateOfAnswer" : {"_value" : "2024-10-31", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-31T14:49:55.293Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Health Education"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential merits of running a public awareness campaign to remove all COVID signs.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : "http://data.parliament.uk/members/5158", "tablingMemberConstituency" : {"_value" : "Great Yarmouth"} , "tablingMemberPrinted" : [{"_value" : "Rupert Lowe"} ], "uin" : "11724"} , {"_about" : "http://data.parliament.uk/resources/1737301", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1737301/answer", "answerText" : {"_value" : "

The study abstract has been reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA), as part of its continuous post approval safety monitoring procedures for the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty). The abstract is available at the following link:<\/p>

https://catalogues.ema.europa.eu/system/files/2024-06/C4591021%20Interim%205%20Study%20Report%20Abstract%20_0.pdf<\/a><\/p>

The MHRA does not consider that any regulatory action is warranted at this time and will review the final study report, when it\u2019s made available by Pfizer, as part of safety monitoring procedures.<\/p>

The MHRA does not publish study reports for company studies, and further publications of results are the responsibility of Pfizer-BioNTech. The MHRA continues to closely monitor the safety of all COVID-19 vaccines and will take any regulatory action necessary should any new safety concerns be identified.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"} } , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"} , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"} , "dateOfAnswer" : {"_value" : "2024-10-31", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-31T12:59:08.553Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-28", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 14 October 2024 to Question 6194 on Coronavirus: Vaccination, whether the Medicines and Healthcare products Regulatory Agency has made an assessment of the potential implications for future medical decisions of the Pfizer study abstract entitled, Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine, dated 12 March 2024; and when he plans to publish the full study.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4084", "label" : {"_value" : "Biography information for Esther McVey"} } , "tablingMemberConstituency" : {"_value" : "Tatton"} , "tablingMemberPrinted" : [{"_value" : "Esther McVey"} ], "uin" : "11248"} , {"_about" : "http://data.parliament.uk/resources/1737148", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1737148/answer", "answerText" : {"_value" : "

NHS England and the integrated care boards are responsible for ensuring that the healthcare needs of local communities are met. These responsibilities include considering adequate healthcare provision, care, and wider support for local populations, including in remote and rural areas.<\/p>

For those who may struggle to access treatment, the NHS Healthcare Travel Costs Scheme provides financial assistance to patients in England who do not have a medical need for transport, but who require assistance with the costs of travelling to receive certain National Health Services. The NHS Non-Emergency Patient Transport Services provide funded transport where a medical condition means that a patient would struggle to safely attend their treatment independently.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"} } , "answeringMemberConstituency" : {"_value" : "Bristol South"} , "answeringMemberPrinted" : {"_value" : "Karin Smyth"} , "dateOfAnswer" : {"_value" : "2024-10-31", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-31T15:47:53.947Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Radiotherapy: Rural Areas"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will have discussions with NHS England on improving access to radiotherapy treatments for cancer patients in rural areas.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/350", "label" : {"_value" : "Biography information for Sir John Hayes"} } , "tablingMemberConstituency" : {"_value" : "South Holland and The Deepings"} , "tablingMemberPrinted" : [{"_value" : "Sir John Hayes"} ], "uin" : "11156"} , {"_about" : "http://data.parliament.uk/resources/1736889", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1736889/answer", "answerText" : {"_value" : "

As set out in the Delivering a Net Zero National Health Service report, published in October 2020, the NHS is committed to reducing its environmental impact, including by increasing the reuse and recycling of medical equipment. This report is available at the following link:<\/p>

https://www.england.nhs.uk/greenernhs/wp-content/uploads/sites/51/2022/07/B1728-delivering-a-net-zero-nhs-july-2022.pdf<\/a><\/p>

In October 2024, the Government published the Design for Life roadmap, a new strategy to transition away from all avoidable single-use medical technology products towards a functioning circular system by 2045. This roadmap is available at the following link:<\/p>

https://www.gov.uk/government/publications/design-for-life-roadmap<\/a><\/p>

The programme is expected to support the NHS by improving resilience, reducing waste, delivering cost savings, and achieving the NHS commitment to be net zero by 2045. The Design for Life roadmap provides examples of where NHS organisations are already achieving cost, waste, and carbon savings through reusing, remanufacturing, and recycling medical devices and equipment, in line with their local Green Plans.<\/p>

In addition, NHS England collaborates with NHS Supply Chain to increase the availability of reusable products, and supports local NHS organisations to use more reusable medical devices and products, where it is safe to do so. For example, NHS England supported the Royal Surgical Colleges to develop the evidence-based Green Theatre Checklist to encourage sustainable theatre approaches, including promoting the use of reusable or remanufactured equipment, where appropriate. Further information on the checklist is available at the following link:<\/p>

https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.rcsed.ac.uk%2Fprofessional-support-development-resources%2Fenvironmental-sustainability-and-surgery%2Fgreen-theatre-<\/a><\/p>

Additionally, NHS England is supporting innovation through the Small Business Research Initiative Healthcare programme, which has funded a project to support reuse of surgical textiles, with further information available at the following link:<\/p>

https://sbrihealthcare.co.uk/impact-case-studies/case-studies/revolution-zero<\/a><\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"} } , "answeringMemberConstituency" : {"_value" : "Bristol South"} , "answeringMemberPrinted" : {"_value" : "Karin Smyth"} , "dateOfAnswer" : {"_value" : "2024-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-29T17:13:37.673Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Plastics"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce the number of single-use items used by the National Health Service.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : "http://data.parliament.uk/members/5034", "tablingMemberConstituency" : {"_value" : "Cannock Chase"} , "tablingMemberPrinted" : [{"_value" : "Josh Newbury"} ], "uin" : "11075"} , {"_about" : "http://data.parliament.uk/resources/1736894", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1736894/answer", "answerText" : {"_value" : "

The Department has made no such assessment. The National Institute for Health and Care Excellence (NICE) makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NICE is currently evaluating rozanolixizumab, zilucoplan, and efgartigimod within their licensed indications for the treatment of myasthenia gravis, and has not yet published final guidance.<\/p>

The Department has received correspondence letters from constituents via their Member of Parliament regarding myasthenia gravis and the treatment for this condition, but there have not been any recent meetings between Ministers and patients with this condition.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"} } , "answeringMemberConstituency" : {"_value" : "Bristol South"} , "answeringMemberPrinted" : {"_value" : "Karin Smyth"} , "dateOfAnswer" : {"_value" : "2024-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-29T16:51:04.317Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Myasthenia Gravis: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of making (a) rozanolixizumab, (b) zilucoplan and (c) efgartigimod available to NHS patients with myasthenia gravis (MG); and what (i) representations his Department has received from and (ii) meetings his Department has had with MG patients on that matter.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4813", "label" : {"_value" : "Biography information for Mr Richard Holden"} } , "tablingMemberConstituency" : {"_value" : "Basildon and Billericay"} , "tablingMemberPrinted" : [{"_value" : "Mr Richard Holden"} ], "uin" : "11055"} , {"_about" : "http://data.parliament.uk/resources/1736913", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1736913/answer", "answerText" : {"_value" : "

No assessment has been made on the impact of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID on economic growth. However, the Government recognises that long-term sickness continues to be the most common reason for economic inactivity among the working age population. As part of the Get Britain Working plan, more disabled people and those with health conditions will be supported to enter and stay in work, by devolving more power to local areas so they can shape a joined-up work, health, and skills offer that suits the needs of the people they serve.<\/p>

The Government has established a Growth Mission Board focused squarely on reviving economic growth, and has established a new Growth Delivery Unit in HM Treasury to track and support delivery of key growth priorities.<\/p>

The final ME/CFS delivery plan is a priority for the Department, and it is our intention to publish a response summary later this autumn. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish this in the winter of 2024/25.<\/p>

The Department funds ME/CFS research through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of ME/CFS, and are actively exploring next steps for research in this area. The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS.<\/p>

Ring-fencing funding for ME/CFS has been considered and discussed with the community during the development of the Interim Delivery Plan for ME/CFS, as well as the recent roundtables on ME/CFS and Long COVID. Ring-fencing is not usual practice for research funders as applications in all areas compete for the funding available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity. Funding for high quality research is available through NIHR programmes, and there is support available for researchers to successfully apply for these awards.<\/p>

Over the last five years, the NIHR has invested over £3.6 million in research programme funding for ME/CFS. This includes over £1.5 million to the DecodeME study, co-funded with the MRC, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"} } , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"} , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"} , "dateOfAnswer" : {"_value" : "2024-10-30", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "10995"} , {"_value" : "10996"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1736913/answer/previousversion/13733", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"} } , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"} , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"} } , "questionFirstAnswered" : [{"_value" : "2024-10-30T16:30:29.643Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Chronic Fatigue Syndrome and Long Covid"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made with the Chancellor of the Exchequer of the potential impact of (a) ME and (b) long covid on economic growth.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4089", "label" : {"_value" : "Biography information for Tessa Munt"} } , "tablingMemberConstituency" : {"_value" : "Wells and Mendip Hills"} , "tablingMemberPrinted" : [{"_value" : "Tessa Munt"} ], "uin" : "10994"} , {"_about" : "http://data.parliament.uk/resources/1736914", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1736914/answer", "answerText" : {"_value" : "

No assessment has been made on the impact of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID on economic growth. However, the Government recognises that long-term sickness continues to be the most common reason for economic inactivity among the working age population. As part of the Get Britain Working plan, more disabled people and those with health conditions will be supported to enter and stay in work, by devolving more power to local areas so they can shape a joined-up work, health, and skills offer that suits the needs of the people they serve.<\/p>

The Government has established a Growth Mission Board focused squarely on reviving economic growth, and has established a new Growth Delivery Unit in HM Treasury to track and support delivery of key growth priorities.<\/p>

The final ME/CFS delivery plan is a priority for the Department, and it is our intention to publish a response summary later this autumn. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish this in the winter of 2024/25.<\/p>

The Department funds ME/CFS research through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of ME/CFS, and are actively exploring next steps for research in this area. The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS.<\/p>

Ring-fencing funding for ME/CFS has been considered and discussed with the community during the development of the Interim Delivery Plan for ME/CFS, as well as the recent roundtables on ME/CFS and Long COVID. Ring-fencing is not usual practice for research funders as applications in all areas compete for the funding available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity. Funding for high quality research is available through NIHR programmes, and there is support available for researchers to successfully apply for these awards.<\/p>

Over the last five years, the NIHR has invested over £3.6 million in research programme funding for ME/CFS. This includes over £1.5 million to the DecodeME study, co-funded with the MRC, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"} } , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"} , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"} , "dateOfAnswer" : {"_value" : "2024-10-30", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "10994"} , {"_value" : "10996"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1736914/answer/previousversion/13735", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"} } , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"} , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"} } , "questionFirstAnswered" : [{"_value" : "2024-10-30T16:30:29.673Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Chronic Fatigue Syndrome and Long Covid"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the delivery plan for ME/CFS will include measures to improve the safety of NHS care for patients with ME.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4089", "label" : {"_value" : "Biography information for Tessa Munt"} } , "tablingMemberConstituency" : {"_value" : "Wells and Mendip Hills"} , "tablingMemberPrinted" : [{"_value" : "Tessa Munt"} ], "uin" : "10995"} , {"_about" : "http://data.parliament.uk/resources/1736915", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1736915/answer", "answerText" : {"_value" : "

No assessment has been made on the impact of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID on economic growth. However, the Government recognises that long-term sickness continues to be the most common reason for economic inactivity among the working age population. As part of the Get Britain Working plan, more disabled people and those with health conditions will be supported to enter and stay in work, by devolving more power to local areas so they can shape a joined-up work, health, and skills offer that suits the needs of the people they serve.<\/p>

The Government has established a Growth Mission Board focused squarely on reviving economic growth, and has established a new Growth Delivery Unit in HM Treasury to track and support delivery of key growth priorities.<\/p>

The final ME/CFS delivery plan is a priority for the Department, and it is our intention to publish a response summary later this autumn. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish this in the winter of 2024/25.<\/p>

The Department funds ME/CFS research through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of ME/CFS, and are actively exploring next steps for research in this area. The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS.<\/p>

Ring-fencing funding for ME/CFS has been considered and discussed with the community during the development of the Interim Delivery Plan for ME/CFS, as well as the recent roundtables on ME/CFS and Long COVID. Ring-fencing is not usual practice for research funders as applications in all areas compete for the funding available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity. Funding for high quality research is available through NIHR programmes, and there is support available for researchers to successfully apply for these awards.<\/p>

Over the last five years, the NIHR has invested over £3.6 million in research programme funding for ME/CFS. This includes over £1.5 million to the DecodeME study, co-funded with the MRC, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"} } , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"} , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"} , "dateOfAnswer" : {"_value" : "2024-10-30", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "10994"} , {"_value" : "10995"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1736915/answer/previousversion/13734", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"} } , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"} , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"} } , "questionFirstAnswered" : [{"_value" : "2024-10-30T16:30:29.72Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Chronic Fatigue Syndrome: Research"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of ring-fencing biomedical research funding for ME.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4089", "label" : {"_value" : "Biography information for Tessa Munt"} } , "tablingMemberConstituency" : {"_value" : "Wells and Mendip Hills"} , "tablingMemberPrinted" : [{"_value" : "Tessa Munt"} ], "uin" : "10996"} , {"_about" : "http://data.parliament.uk/resources/1736935", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1736935/answer", "answerText" : {"_value" : "

The Mental Health Bill announced in the King\u2019s Speech will deliver the Government\u2019s commitment to modernise the Mental Health Act 1983. The bill will be published when Parliamentary time allows.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4359", "label" : {"_value" : "Biography information for Stephen Kinnock"} } , "answeringMemberConstituency" : {"_value" : "Aberafan Maesteg"} , "answeringMemberPrinted" : {"_value" : "Stephen Kinnock"} , "dateOfAnswer" : {"_value" : "2024-10-31", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-31T11:39:36.923Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Mental Health Act 1983"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, when his Department plans to bring forward legislative proposals to update the Mental Health Act 1983.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : "http://data.parliament.uk/members/5142", "tablingMemberConstituency" : {"_value" : "Sheffield Central"} , "tablingMemberPrinted" : [{"_value" : "Abtisam Mohamed"} ], "uin" : "11096"} , {"_about" : "http://data.parliament.uk/resources/1736946", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1736946/answer", "answerText" : {"_value" : "

I refer the Hon. Member to the answer I gave on 9 September 2024 to Question 2902<\/a>.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"} } , "answeringMemberConstituency" : {"_value" : "Bristol South"} , "answeringMemberPrinted" : {"_value" : "Karin Smyth"} , "dateOfAnswer" : {"_value" : "2024-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-29T17:09:18.387Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Prescriptions"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress his Department has made on the implementation of the recommendations of his Department's report entitled Good for you, good for us, good for everybody: A plan to reduce overprescribing to make patient care better and safer, support the NHS, and reduce carbon emissions, published on 22 September 2021.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"} } , "tablingMemberConstituency" : {"_value" : "Rotherham"} , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"} ], "uin" : "11003"} ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&answeringDeptSortName=Health+and+Social+Care&min-ddpModified.=2019-09-09T18%3A00%3A06.953Z", "page" : 0, "startIndex" : 1, "totalResults" : 50407, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }